Drugs / HEC121120
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04536532 | Oct 2020 → Mar 2023 | chronic hepatitis B virus infection | Sunshine Lake Pharma Co., Ltd. | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HEC121120 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04536532 ↗ |
| Route | Oral | “Each dose of HEC121120 and placebo will be administered with approximately 240 mL of water in the morning after fasting for at least 10 hours overnight.” NCT04536532 ↗ |